Generic Name: ofatumumab
Brand Name: TBC
Manufacturer: Novartis Pharmaceuticals Canada Inc.
Indications: Multiple Sclerosis, relapsing
Manufacturer Requested Reimbursement Criteria1: For the treatment of Relapsing Multiple Sclerosis (RMS)
Submission Type: New
Project Status: Pending
Call For Patient Input: July 27, 2020
Patient Input Closed: September 16, 2020
Anticipated Date: August 25, 2020
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.